# Biochemistry Problems Synthesis

## Research Sources
- **Grok (xAI)**: 10 problems with feasibility ratings
- **Gemini (Google)**: 12 problems with formal verification approaches
- **Task Agent**: (In progress - 14+ web searches)

## Ranking Criteria
1. **Business Impact**: Cost of failure ($100M-$1B+)
2. **Feasibility**: Can it be formalized in Lean 4? (High/Moderate/Low)
3. **Novelty**: Is anyone else doing this?

---

## Top 10 Problems for GitHub Issues

### üü¢ HIGH FEASIBILITY (Implement First)

#### 1. PK/PD Modeling Failures ‚≠ê **TOP PRIORITY**
- **Cost**: $300M+ per failure
- **Feasibility**: **HIGH** - Already mathematical models
- **What to Prove**: Drug exposure stays within safe/effective range
- **Grok**: "Most feasible - models are already differential equations"
- **Gemini**: Not covered (focus on molecular)
- **Action**: Issue #1 - Prove PK/PD parameter bounds

#### 2. Solubility & Bioavailability
- **Cost**: $200M+ per failure
- **Feasibility**: **HIGH** - Thermodynamic models well-defined
- **What to Prove**: Solubility above therapeutic threshold
- **Grok**: "Moderate to High - formalization straightforward"
- **Gemini**: Not covered
- **Action**: Issue #2 - Prove minimum solubility constraints

### üü° MODERATE FEASIBILITY (Core Research Program)

#### 3. hERG Cardiac Toxicity (QT Prolongation) ‚≠ê **CRITICAL**
- **Cost**: $500M+ per failure + lawsuits + most common Phase III failure
- **Feasibility**: **MODERATE** - Geometric constraints possible
- **What to Prove**: Drug CANNOT bind to hERG channel (geometric exclusion)
- **Grok**: "Moderate - requires structural data but doable"
- **Gemini**: "Geometric constraint solving - prove pharmacophore ‚à© pore = ‚àÖ"
- **Example**: Terfenadine (Seldane), Cisapride
- **Action**: Issue #3 - Prove geometric incompatibility with hERG

#### 4. Blood-Brain Barrier Permeability
- **Cost**: $400M+ per CNS drug failure
- **Feasibility**: **MODERATE** - Lipinski rules + transporter kinetics
- **What to Prove**: Drug achieves brain-to-plasma ratio above threshold
- **Grok**: "Moderate - physicochemical rules formalizable"
- **Gemini**: "Game theory - drug vs P-gp transporter"
- **Example**: Semagacestat (Alzheimer's), Loperamide
- **Action**: Issue #4 - Prove BBB penetration OR exclusion

#### 5. Off-Target Kinase Binding
- **Cost**: $300M+ per oncology failure
- **Feasibility**: **MODERATE to HIGH** - Finite kinome, binding pockets
- **What to Prove**: Binding affinity to off-targets below toxicity threshold
- **Grok**: "Moderate to High - can verify specificity for finite set"
- **Gemini**: Not covered in detail
- **Example**: Sunitinib (cardiotoxicity)
- **Action**: Issue #5 - Prove kinase selectivity panel

#### 6. Non-Specific Target Binding
- **Cost**: $300M+ per failure
- **Feasibility**: **MODERATE** - Docking scores for limited targets
- **What to Prove**: Drug doesn't bind known off-targets
- **Grok**: "Moderate - limited set of targets"
- **Gemini**: (Covered under various categories)
- **Example**: Rofecoxib (Vioxx)
- **Action**: Issue #6 - Prove off-target panel safety

### üî¥ LOW FEASIBILITY (Advanced Research)

#### 7. CYP450 Drug-Drug Interactions
- **Cost**: $300M+ per failure
- **Feasibility**: **LOW to MODERATE** - Complex enzyme dynamics
- **What to Prove**: Drug doesn't inhibit/induce CYP450 enzymes
- **Grok**: "Low to Moderate - too much chemical space"
- **Gemini**: "Deadlock detection in process algebra"
- **Example**: Mibefradil, Cerivastatin + Gemfibrozil
- **Action**: Issue #7 - Explore CYP450 formalization (research phase)

#### 8. Reactive Metabolite Formation
- **Cost**: $400M+ per hepatotoxicity failure
- **Feasibility**: **LOW** - Exhaustive reaction modeling needed
- **What to Prove**: No toxic metabolites formed
- **Grok**: "Low - data-limited and computationally intensive"
- **Gemini**: "Reachability analysis in metabolic network Petri nets"
- **Example**: Troglitazone, Acetaminophen (NAPQI)
- **Action**: Issue #8 - Research metabolic pathway formalization

#### 9. Protein Aggregation (Biologics)
- **Cost**: $500M+ per biologic failure
- **Feasibility**: **LOW** - Chaotic high-dimensional dynamics
- **What to Prove**: Protein won't aggregate under storage conditions
- **Grok**: "Low - protein folding too complex"
- **Gemini**: "Barrier certification from control theory"
- **Example**: Eprex (PRCA), Adalimumab biosimilars
- **Action**: Issue #9 - Explore aggregation energy barriers

#### 10. Allosteric Modulation Effects
- **Cost**: $300M+ per failure
- **Feasibility**: **LOW** - Protein dynamics beyond current methods
- **What to Prove**: No functional allosteric binding
- **Grok**: "Low - conformational changes too complex"
- **Gemini**: "Temporal logic for conformational hysteresis"
- **Example**: GPCR modulators, Gefitinib
- **Action**: Issue #10 - Research allosteric site formalization

---

## Special Mentions from Gemini (Not in Grok)

### 11. Lysosomal Trapping (Cationic Amphiphilic Drugs)
- **Cost**: Phase I toxicity
- **Feasibility**: **MODERATE** - Invariant generation for pH gradients
- **Gemini**: "Prove accumulation ratio < safety threshold"
- **Example**: Chloroquine, Amiodarone
- **Action**: Issue #11 - Prove lysosomal accumulation bounds

### 12. Stereochemical Inversion In Vivo
- **Cost**: Patent loss + toxicity (Thalidomide-like)
- **Feasibility**: **MODERATE** - Graph transformation rules
- **Gemini**: "Prove no valid reaction path from Isomer A ‚Üí B"
- **Example**: Thalidomide, Ibuprofen
- **Action**: Issue #12 - Prove stereochemical stability

### 13. Cytokine Storm (Super-Agonism)
- **Cost**: **CATASTROPHIC** - Phase I deaths
- **Feasibility**: **LOW to MODERATE** - Hybrid systems stability
- **Gemini**: "Prove closed-loop gain < 1 (stable signaling)"
- **Example**: TGN1412 disaster
- **Action**: Issue #13 - Research immune cascade stability

### 14. HLA-Mediated Immune Reactivity
- **Cost**: Stevens-Johnson Syndrome, drug withdrawal
- **Feasibility**: **MODERATE** - SAT solving for binding groove
- **Gemini**: "Prove drug conformation UNSATISFIABLE in HLA groove"
- **Example**: Abacavir, Carbamazepine
- **Action**: Issue #14 - Prove HLA allele incompatibility

---

## Implementation Strategy

### Phase 1: Quick Wins (2-4 weeks)
- Issue #1 (PK/PD) - Prove parameter bounds
- Issue #2 (Solubility) - Prove threshold satisfaction
- **Goal**: Demonstrate Lean can handle drug discovery problems

### Phase 2: Core Value (1-3 months)
- Issue #3 (hERG) - THE critical problem ($500M+ failures)
- Issue #4 (BBB) - Major CNS drug issue
- Issue #5 (Kinase selectivity) - Oncology standard
- **Goal**: Prove one property that prevents a real drug failure

### Phase 3: Advanced Research (3-6 months)
- Issue #7 (CYP450) - Complex but high-impact
- Issue #11 (Lysosomal trapping) - Novel approach
- Issue #12 (Stereochemistry) - Elegant proof
- **Goal**: Publishable novel results

### Phase 4: Moonshots (6-12 months)
- Issue #8 (Reactive metabolites) - Metabolic networks
- Issue #9 (Aggregation) - Biologic stability
- Issue #13 (Cytokine storm) - Control theory application
- **Goal**: Nature/Science publication

---

## Key Insights from Multi-AI Research

### Agreement (All 3 AIs)
1. **hERG toxicity** is the #1 most important problem
2. **PK/PD modeling** is the most mathematically mature
3. **Geometric constraints** are more feasible than dynamic modeling
4. **Business impact** justifies even partial solutions

### Disagreement
- **Grok** is more conservative on feasibility
- **Gemini** proposes more advanced formal methods (Petri nets, barrier certificates)
- Need to validate which approaches Aristotle can actually handle

### Gaps to Fill (When Task Agent Completes)
- Specific drug examples and failure costs
- Recent 2024-2025 failures
- Quantitative success metrics

---

## Next Actions

1. ‚úÖ Create GitHub issues for top 10-14 problems
2. ‚è≥ Wait for Task agent to complete
3. ‚è≥ Integrate Task agent findings
4. ‚è≥ Launch audit workflow for each issue
5. ‚è≥ Prioritize based on feasibility + impact

**Estimated Time**: 2-3 hours for full research ‚Üí validated issues pipeline
